SCHEMBL2900632

SCHEMBL2900632

CSc1ncc(C(=O)O)c(NCc2ccco2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.58
LMNA P02545 3/20 0.58
HPGD P15428 1/20 0.58
KDM6B O15054 1/20 0.51
KDM4A O75164 1/20 0.51
KDM5C P41229 1/20 0.51
KDM4D Q6B0I6 1/20 0.51
KDM4C Q9H3R0 1/20 0.51
REN P00797 3/20 0.48
ALDH1A1 P00352 5/20 0.47
MAPK1 P28482 3/20 0.47
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
HSD17B10 Q99714 3/20 0.44
PKM P14618 1/20 0.44
HTT P42858 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
AURKA O14965 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902099 0.84 REN (0.55) KDM4ELMNAHPGDKDM6BKDM4A
SCHEMBL2902514 0.82 KDM4E (0.52) KDM4ELMNAHPGDKDM6BKDM4A
SCHEMBL2898714 0.82 REN (0.57) KDM4ELMNAHPGDRENMAPK1
SCHEMBL1522370 0.82 PPARG (0.62) KDM4EKDM6BKDM4AKDM4DKDM4C
SCHEMBL2897225 0.81 REN (0.57) KDM4ELMNAKDM6BKDM4AKDM5C
SCHEMBL2892637 0.81 REN (0.57) KDM4ELMNAKDM6BKDM4AKDM5C
SCHEMBL2902262 0.80 PDE5A (0.58) KDM4ELMNAKDM6BKDM4AKDM5C
SCHEMBL2902712 0.79 REN (0.68) KDM4ELMNAHPGDKDM6BKDM4A
SCHEMBL2900583 0.79 KDM4E (0.51) KDM4ELMNAKDM6BKDM4AKDM5C
SCHEMBL2902359 0.79 REN (0.52) KDM4ELMNAHPGDRENMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT KDM4E 1257/4885LMNA 1806/4885HPGD 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.